Janux Therapeutics (NASDAQ:JANX) Stock Rating Upgraded by Wall Street Zen

Janux Therapeutics (NASDAQ:JANX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also weighed in on the company. Truist Financial initiated coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price objective for the company. Barclays lifted their price objective on Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday. Piper Sandler initiated coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $42.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus restated a “buy” rating and set a $45.00 target price on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.17.

Janux Therapeutics Price Performance

Shares of JANX opened at $26.48 on Friday. The firm has a market cap of $1.59 billion, a P/E ratio of -15.76 and a beta of 2.83. Janux Therapeutics has a 1 year low of $21.73 and a 1 year high of $71.71. The company has a 50 day simple moving average of $25.11 and a two-hundred day simple moving average of $25.19.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, sell-side analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total transaction of $500,949.90. Following the completion of the transaction, the insider owned 82,139 shares in the company, valued at $2,469,098.34. The trade was a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 29.40% of the stock is currently owned by insiders.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE boosted its stake in shares of Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after purchasing an additional 1,658 shares during the period. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares during the period. Virtus Investment Advisers LLC grew its stake in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in shares of Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after acquiring an additional 820 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.